{"id":"https://openalex.org/W3028638407","doi":null,"title":"Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC","display_name":"Phase III KEYNOTE-177 Study of Pembrolizumab Doubles PFS in MSI-H/dMMR mCRC","publication_year":2020,"publication_date":"2020-05-28","ids":{"openalex":"https://openalex.org/W3028638407","mag":"3028638407"},"language":"en","primary_location":{"id":"mag:3028638407","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/asco/phase-iii-keynote-177-study-pembrolizumab-doubles-pfs-msi-hdmmr-mcrc","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051642189","display_name":"Hannah Slater","orcid":"https://orcid.org/0000-0003-4291-7899","observed_orcids":["https://orcid.org/0000-0003-4291-7899"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Hannah Slater","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4291-7899","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5051642189"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0991,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.40448825,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":92},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.7904999852180481,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.7904999852180481,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.15610000491142273,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.049300000071525574,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/microsatellite-instability-high","display_name":"microsatellite instability-high","score":0.8700000047683716},{"id":"https://openalex.org/keywords/mismatch-repair-deficiency","display_name":"mismatch repair deficiency","score":0.9520000219345093},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7739999890327454},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7400000095367432},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9390000104904175},{"id":"https://openalex.org/keywords/chemotherapy-comparison","display_name":"chemotherapy comparison","score":0.5690000057220459}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.871773362159729},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5386277437210083},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4353381097316742},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.41964563727378845},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26984089612960815},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.12132346630096436}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:3028638407","doi":null,"is_oa":false,"landing_page_url":"https://www.cancernetwork.com/asco/phase-iii-keynote-177-study-pembrolizumab-doubles-pfs-msi-hdmmr-mcrc","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3109553199","https://openalex.org/W4387809627","https://openalex.org/W3186516733","https://openalex.org/W3033652843","https://openalex.org/W2589296110","https://openalex.org/W3124887287","https://openalex.org/W4231061296","https://openalex.org/W2905022081","https://openalex.org/W4404923724","https://openalex.org/W2890568307"],"abstract_inverted_index":{"Front-line":[0],"therapy":[1],"with":[2,11],"pembrolizumab":[3],"doubled":[4],"progression-free":[5],"survival":[6],"versus":[7],"chemotherapy":[8],"in":[9],"patients":[10],"microsatellite":[12],"instability-high":[13],"or":[14],"mismatch":[15],"repair":[16],"deficient":[17],"metastatic":[18],"colorectal":[19],"cancer.":[20]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2020-06-05T00:00:00"}